Online CME

Faculty Biographies

How to Obtain AMA PRA Category 1 Credit

  1. Complete the Activity.
  2. Complete the CME posttest (each question must be answered correctly).
  3. Log into your myCME account.
  4. Complete the credit and evaluation form.
  5. Print your personalized CME certificate.
  6. Credit can only be claimed once for this activity.

Technical Requirements

Tumor Board Series

Management of Locally
Advanced HER2-Positive Breast Cancer

Print this Content


Release Date:   March 11, 2015
Renewal Date:   March 11, 2016
Expiration Date:  March 11, 2017

Estimated Time of Completion: 1 hour


This webcast provides expert insight on optimizing treatment of patients with HER2-positive early-stage/locally advanced breast cancer. It will consist of a case presentation of a patient with HER2-positive early-stage/locally advanced disease. Suggested treatment options based on best practices, current treatment guidelines, and data from relevant recent clinical trials will be discussed. Expert faculty will present various aspects of the case, including radiolologic imaging, pathologic findings (particularly HER2 testing), and options for neoadjuvant therapy with HER2-targeted agents. Recommendations regarding surgical resection, options for adjuvant therapy with chemotherapy and targeted agents, and radiation therapy post-surgery also will be addressed.

Learning Objectives

  1. Assess the role of neoadjuvant chemotherapy in HER2-positive breast cancer, including use of HER2-targeted agents (trastuzumab, pertuzumab, ado-trastuzumab emtansine).
  2. Discuss FDA approval of HER2-targeted agents for breast cancer, based on neoadjuvant data and use of pathological complete response (pCR) as a surrogate marker.
  3. Review HER2 testing guidelines (ASCO-CAP) for patients with breast cancer.
  4. State the indications for breast magnetic resonance imaging (MRI).
  5. Appraise recent and ongoing clinical trials of adjuvant therapy in HER2-positive breast cancer.
  6. Assess local treatment after neoadjuvant surgery.
  7. Summarize key Phase 3 trials of HER2-targeted neoadjuvant therapy including NeoALTTO (lapatinib, trastuzumab, or combination in addition to paclitaxel), and ongoing NSABP B-50-I Phase 3 trial (KATHERINE) of trastuzumab plus emtansine as adjuvant therapy.

Target Audience

This activity is designed for health care practitioners including medical oncologists, surgical oncologists and general surgeons, radiation oncologists, radiologists, pathologists, and other health care professionals who manage patients with breast cancer.


The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

Activity Director and Faculty

Activity Director and Faculty
Jame Abraham, MD

Jame Abraham, MD
Director, Breast Oncology Program at Taussig Cancer Institute
Co-Director of the Cleveland Clinic Multidisciplinary Breast Cancer Program
Cleveland Clinic
Cleveland, Ohio


Benjamin C. Calhoun, MD, PhD
Director, Breast Pathology
Assistant Professor of Pathology
Department of Pathology
Cleveland Clinic
Cleveland, Ohio

Stephen R. Grobmyer, MD
Professor of Surgery-Lerner College of Medicine Case Western University
Director, Section of Surgical Oncology
Cleveland Clinic
Cleveland, Ohio

Eleftherios (Terry) P. Mamounas, MD, MPH, FACS
Medical Director, Comprehensive Breast Program
UF Health Cancer Center at Orlando Health
Professor of Surgery, University of Central Florida College of Medicine
Clinical Professor of Clinical Sciences at Florida State University College of Medicine
Orlando, Florida

Halle Moore, MD
Department of Hematology and Medical Oncology
Taussig Cancer Center
Cleveland Clinic,
Cleveland, Ohio

Mikkael Sekeres, MD, MS
Professor of Medicine
Director of the Leukemia Program
Vice Chair for Clinical Research at the Cleveland Clinic Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio

Laura Shepardson, MD
Breast Imaging
Cleveland Clinic
Cleveland, Ohio

Rahul Tendulkar, MD
Assistant Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Associate Staff Physician, Department of Radiation Oncology
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

CME Disclaimer

The information in this educational activity is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition. The viewpoints expressed in this CME activity are those of the authors/faculty. They do not represent an endorsement by The Cleveland Clinic Foundation. In no event will The Cleveland Clinic Foundation be liable for any decision made or action taken in reliance upon the information provided through this CME activity.


In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty have indicated that they may have a relationship, which in the context of their presentations, could be perceived as a potential conflict of interest:

Terry Mamounas, MD
  Genentech/Roche Teaching and Speaking
  Genomic Health, Inc. Teaching and Speaking; Consulting; Membership on Advisory Committee
  Pfizer; GSK; Celgene; Eisai Consulting; Membership on Advisory Committee
Larry Rosenberg, PhD
  Pfizer; Bayer Ownership Interest; Employment

The following faculty have indicated they have no relationship which, in the context of their presentations, could be perceived as a potential conflict of interest:

Jame Abraham, MD
Benjamin Calhoun, MD, PhD
Stephen Grobmyer, MD
Halle Moore, MD
Mikkael Sekeres, MD
Laura Shepardson, MD
Rahul Tendulkar, MD

All other planners, CME staff, and content reviewers, have no relevant financial relationships to disclose.

The Cleveland Clinic Foundation Center for Continuing Education acknowledges an educational grant for partial support of this activity from:

Genentech, Inc.

This CME activity was produced by the Cleveland Clinic Foundation Center for Continuing Education, Taussig Cancer Institute and Haborside Press.